The US Federal Trade Commission's antitrust complaint against Reckitt Benckiser Group PLC for its promotion of Suboxone film (buprenorphine/naloxone) as less susceptible to accidental pediatric exposure than the tablet formulation shows the kind of product hopping behavior the agency may pursue in the future.
The agency has expressed interest in going after drug makers for so-called product hopping, in which a drug manufacturer tries...





